Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Mark E McGovern

Adeoye Y Olukotun

Bruce D Behounek

Miguel A Ondetti

Henry Y Pan

Martin Eisman

A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.

Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor

Method for preventing or reducing risk of onset of cardiovascular events

Method for preventing reducing or risk of onset of cerebrovascular

A method is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication employing a cholesterol lowering drug such as an HMG CoA reductase inhibitor alone and/or an inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil; employing an ACE inhibitor alone such as captopril or ceranapril; or a combination of a cholesterol lowering drug and an ACE inhibitor.

Method for treating peripheral atherosclerotic disease employing a

A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering pravastatin alone or in combination with an ACE inhibitor such as captopril or ceranapril, prior to, during and/or after angioplasty.

Method for preventing onset of restenosis after angioplasty employing

Growing community of inventors

Philadelphia, PA, United States of America

Mark E McGovern